- Home
- RY vs AMGN Comparison
RY vs AMGN Comparison
Compare RY & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RY
- AMGN
- Stock Information
- Founded
- RY 1864
- AMGN 1980
- Country
- RY Canada
- AMGN United States
- Employees
- RY N/A
- AMGN N/A
- Industry
- RY
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RY
- AMGN Health Care
- Exchange
- RY Nasdaq
- AMGN Nasdaq
- Market Cap
- RY 175.6B
- AMGN 141.6B
- IPO Year
- RY N/A
- AMGN N/A
- Fundamental
- Price
- RY $122.30
- AMGN $274.81
- Analyst Decision
- RY Strong Buy
- AMGN Buy
- Analyst Count
- RY 2
- AMGN 22
- Target Price
- RY $156.50
- AMGN $324.05
- AVG Volume (30 Days)
- RY 928.3K
- AMGN 3.5M
- Earning Date
- RY 02-26-2025
- AMGN 02-04-2025
- Dividend Yield
- RY 3.45%
- AMGN 3.45%
- EPS Growth
- RY 9.01
- AMGN N/A
- EPS
- RY 8.07
- AMGN 7.83
- Revenue
- RY $38,831,718,701.00
- AMGN $32,534,000,000.00
- Revenue This Year
- RY N/A
- AMGN $20.07
- Revenue Next Year
- RY $5.53
- AMGN $3.59
- P/E Ratio
- RY $15.14
- AMGN $35.08
- Revenue Growth
- RY 10.44
- AMGN 21.25
- 52 Week Low
- RY $93.97
- AMGN $253.30
- 52 Week High
- RY $128.05
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- RY 55.06
- AMGN 57.51
- Support Level
- RY $119.01
- AMGN $267.15
- Resistance Level
- RY $123.17
- AMGN $276.97
- Average True Range (ATR)
- RY 1.49
- AMGN 4.91
- MACD
- RY 0.24
- AMGN 2.54
- Stochastic Oscillator
- RY 84.30
- AMGN 89.16
About RY Royal Bank Of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the US and other countries.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.